According to its manufacturer of Diabeticine, Diabeticine has been shown to be 99% effective for Type 2 and 64% effective for Type 1 at reversing the root cause of diabetes, based on clinical studies and over two years of use. (Please see FDA's warnings below)
Diabeticine contains all-natural ingredients. According to its manufacturer, Diabeticine contains no chemically generated compounds, fillers, or artificial additives. The manufacturer also states that "Diabeticine correctly solves the root cause of the problem, ... and not merely mask the symptoms". (Please see FDA's warnings below)
Finally, the manufacturer also assures that "Diabeticine is proven to be successful and goes to the cellular level to lower your blood sugar level, lower your insulin resistance, and increase insulin production." (Please see FDA's warnings below)
A statement listed on Diabeticine's manufacturer's website:
"I feel very fortunate to have the privilege of working with Dr. Thao in the research and development of Diabeticine. We took extra measure to make sure that the formula has integrity, scientific validation and effectiveness in the fight against diabetes. I am proud to recommend Diabeticine to anyone with Type 1 or Type 2 diabetes."
Dr. Judy Hamilton, MD, PhD
However, please note that in a letter from the US Food and Drug Administration (FDA) dated August 16, 2005, FDA states that "above statements are promoted for conditions that cause Diabeticine to be a drug under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)]. The therapeutic claims on the manufacturer's website establish that Diabeticine to be a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of Diabeticine with these claims violates the Act."
FDA also lists other examples of the medical claims of Diabeticine, which included the followings:
“Reverse the Root Cause of Diabetes”
In FDA's letter, it further states that Diabeticine is "not generally
recognized as safe and effective for the above referenced condition and
therefore, these products are also “new drugs” under section 201(p) of the
Act [21 U.S.C. § 321(p)]. New drugs may not be legally marketed in the U.S.
without prior approval from FDA as described in section 505(a) of the Act
[21 U.S.C. § 355(a)]. FDA approves new drugs on the basis of scientific data
submitted by a drug sponsor to demonstrate that the drugs are safe and
contact us for